When SSRIs fail: the neuromodulation pathway

Device-based neuromodulation therapies may offer a viable alternative for patients with depression who do not achieve adequate response to SSRIs. Device-based neuromodulation therapies may offer a viable alternative for patients with depression who do not achieve adequate response to SSRIs. According to GlobalData analysis, the global neuromodulation device market is projected to reach a valuation approaching of over $13bn in 2035, up from around $6.8bn in 2025. Credit: Dadann / Shutterstock.com Selective serotonin reuptake inhibitors (SSRIs) are considered the first-line, gold standard treatment for depression. However, their use is not without limitations, with commonly reported side effects including weight gain,…

Source: Medical Device Network